Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Sutro Biopharma, Inc.NASDAQ: STRO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$27.75M, compared with -$45.57M a year earlier. Trailing-twelve-month EBITDA was -$106.12M.

Context

  • EBITDA amounted to 142.1% of revenue in FY2025, down 148.7 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of -$28.89M (+80.2%) for the fiscal year ending Dec 2026, a step up from the +19.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$27.75M+20.5% QoQ
Last fiscal yearDec 2025
-$145.65M+19.3% YoY
LTMMar 2026
-$106.12M+42.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.1%-2451.9%-2491.0 pp
1 year+19.3%+80.2%+60.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(145.65M) USD
Year-over-year change
+19.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +42.0% is the 2nd highest of 9, against a peer median of -9.8%.
  • EBITDA amounts to 106.5% of revenue for STRO, versus a peer median of 44951.4%.
STRO Competitors
EBITDA for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M USD-143.9%—89.7%
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.08M USD+36.5%——
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M USD-270.2%—85279.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$84.44M USD-35.4%——
STROSutro Biopharma, Inc.LTM Mar 2026-$106.12M USD+42.0%—106.5%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$106.88M USD-21.2%——
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$107.98M USD+49.6%——
Peer median (excluding STRO) —-9.8%—44951.4%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.